|
| |
Alimera SciencesOur name, Alimera, is a loose combination of ancient Greek words with the intended meaning of "Day of Truth" and is founded on the underlying principles of honesty, integrity, responsibility, candor, and trust. We recognize that everyday we have the opportunity to impact the lives of doctors, patients, partners, shareholders, family and friends and we understand the importance of these relationships. At Alimera Sciences, we believe in doing the right thing and knowing the right things to do. It is these qualities that shape Alimera Sciences' culture and that will ultimately benefit our corporate partners, our shareholders, and the customers we serve.
Mission
Alimera Sciences is a new kind of pharmaceutical company that's focused on doing the right thing and knowing the right things to do. Because of our deep industry experience, knowledge and relationships, we are able to rapidly bring forth meaningful products to eyecare. We approach all interactions with a win/win mindset and the goal of proving that an ethically-driven company can greatly impact value.
| Contact Details: |
| 6120 Windward Parkway, Suite 290 |
| Alpharetta |
| Georgia |
| 30005 |
| United States of America |
| Tel: | 678.990.5740 |
| Fax: | 678.990.5744 |
| Email: | |
| WWW: | www.alimerasciences.com/
|
|
Loading...
|
Press Releases on Alimera Sciences:
|
 |
| Ocular Therapeutix, Inc. Appoints Two New Board Members |
1st October, 2009 |
Ocular Therapeutix, Inc. |
WALTHAM, Mass., Oct. 1 /PRNewswire/ -- Ocular Therapeutix, Inc. announced today the expansion of its board of directors with the appointment of Mr. Daniel Myers and Mr. Bernard Haffey.
Mr. Myers is
|
| Alimera Reports Safety and Efficacy Results From the 18-Month Interim Readout of the Human PK Iluvien(R) Study |
29th September, 2009 |
Alimera Sciences, Inc. |
ATLANTA, Sept. 29 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic
|
| Alimera Sciences Begins Pilot Study of Iluvien(R) in Patients With Macular Edema Secondary to Retinal Vein Occlusion |
23rd September, 2009 |
Alimera Sciences, Inc. |
ATLANTA, Sept. 23 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic
|
| Alimera Sciences Closes $5 Million in Extended Series C Financing |
27th August, 2009 |
Alimera Sciences, Inc. |
ATLANTA, Aug. 27 /PRNewswire/ -- Alimera Sciences, Inc., today announced that it has closed a $5 million extension of its Series C financing which was originally completed in March 2008. In
|
| Alimera Sciences Announces Presentation of Data From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study at ARVO 2009 Annual Meeting |
4th May, 2009 |
Alimera Sciences, Inc. |
ATLANTA, May 4 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 213 times since April 2007, the link to the organisation's website has been followed 37 times Search for more companies in Alpharetta Search for more companies in Georgia This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Alimera Sciences |
